EP1597353A4
CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
Abstract
A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials.
Term
Term ended
Projected expiry passed 26 February 2024, 2.6 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 2 of 3
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| US2002098535A1 | Cites | United States of America | X | Search report | 1-21 |
| US2002172987A1 | Cites | United States of America | X | Search report | 1-21 |
| KAGAN M ET AL: "A SAMPLE PREPARATION AND ANALYSIS SYSTEM FOR IDENTIFICATION OF CIRCULATING TUMOR CELLS", JOURNAL OF CLINICAL LIGAND ASSAY, CLINICAL LIGAND ASSAY SOCIETY, WAYNE, MI, US, vol. 25, no. 1, 21 March 2002 (2002-03-21), pages 104 - 110, XP008052823, ISSN: 1081-1672 | Non-patent | – | – | Search report | – |
| WITZIG THOMAS E ET AL: "Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH MAY 2002, vol. 8, no. 5, May 2002 (2002-05-01), pages 1085 - 1091, XP002451219, ISSN: 1078-0432 | Non-patent | – | – | Search report | – |
| PITUCH-NOWOROLSKA ANNA ET AL: "Evaluation of circulating tumour cells expressing CD44 variants in the blood of gastric cancer patients by flow cytometry", ANTICANCER RESEARCH, vol. 18, no. 5B, September 1998 (1998-09-01), pages 3747 - 3752, XP008083618, ISSN: 0250-7005 | Non-patent | – | – | Search report | – |
| SABILE A ET AL: "Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, PHILADELPHIA, PA, US, vol. 112, no. 2, August 1999 (1999-08-01), pages 171 - 178, XP009028763, ISSN: 0002-9173 | Non-patent | – | – | Search report | – |
| DOUDINA OLGA ET AL: "Circulating tumor cells in patients with localized breast cancer", BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), & 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 2; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 341b, XP008083708, ISSN: 0006-4971 | Non-patent | – | – | Search report | – |
| PACHMANN K ET AL: "REAL TIME MONITORING OF THE EFFICACY OF ADJUVANT THERAPY IN BREAST CANCER QUANTIFYING THE REDUCTION OF CIRCULATING TUMOR CELLS BY MAINTRAC (LASER SCANNING CYTOMETRY OF MAGNETIC BEAD ENRICHED CELLS)", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 64, no. 1, November 2000 (2000-11-01), pages 96, XP009017863, ISSN: 0167-6806 | Non-patent | – | – | Search report | – |
13 members in 7 offices
Priority claims14
| Document | Office | Kind | Date |
|---|---|---|---|
| 450519P | United States of America | – | |
| 45051903 | United States of America | P | |
| 45051903 | United States of America | P | |
| 524759P | United States of America | – | |
| 52475903 | United States of America | P | |
| 52475903 | United States of America | P | |
| 2004005848 | United States of America | W | |
| 2004005848 | United States of America | W | |
| 450519P | – | – | – |
| 524759P | – | – | – |
| US20030450519P | – | – | – |
| US20030524759P | – | – | – |
| US2004005848 | – | – | – |
| WO2004US05848 | – | – | – |
Members13
| Document | Office | Kind | |
|---|---|---|---|
| CA2516795A1 | Canada | A1 | |
| WO2004076643A2 | World Intellectual Property Organization (WIPO) | A2 | |
| EP1597353A2 | European Patent Office (EPO) | A2 | |
| WO2004076643A3 | World Intellectual Property Organization (WIPO) | A3 | |
| JP2007525642A | Japan | A | |
| EP1597353A4This record | European Patent Office (EPO) | A4 | |
| EP1597353B1 | European Patent Office (EPO) | B1 | |
| JP4593557B2 | Japan | B2 | |
| AT489452T | Austria | T | |
| ATE489452T1 | Austria | T1 | |
| DE602004030220D1 | Germany | D1 | |
| ES2356738T3 | Spain | T3 | |
| CA2516795C | Canada | C |
70 legal events, as 9 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expiredExpiredMK9A | MK9A | IE | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Patent expired because of reaching the maximum lifetime of a patentExpiredMK | MK | BE | |
| Patent expired because of reaching the maximum lifetime of a patentExpiredMK | MK | NL | |
| Expiry of rightR071 | R071 | DE | |
| Opt-out of the competence of the unified patent court (upc) registeredP01 | P01 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097 | R097 | DE | |
| No opposition filedOpposition26N | 26N | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Translation filed for an european patent granted for nl, confirming art. 52 par. 1 or 6 of the patents act 1995GrantedT3 | T3 | NL | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Supplementary search report drawn up and despatchedA4 | A4 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Availability of information related to the publication of the international search reportORIGINAL CODE: 0009015PUAK | PUAK | EP | |
| Request for extension of the european patent (deleted)DAX | DAX | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1597353
- Publication, DOCDB
- 1597353
- Publication, EPODOC
- EP1597353
- Application
- 4715133
- Application, DOCDB
- 04715133
- Application, EPODOC
- EP20040715133
Titles3
- German
- ZIRKULIERENDE TUMORZELLEN (CTCS): FRÜHE BEURTEILUNG VON TIME-TO-PROGRESSION, ÜBERLEBEN UND ANSPRECHEN AUF THERAPIE BEI PATIENTEN MIT METASTASIERTEM KREBS
- English
- CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
- French
- CELLULES TUMORALES CIRCULANTES (CTC): EVALUATION PRECOCE DU TEMPS D'EVOLUTION, DE LA SURVIE ET DE LA REACTION AUX THERAPIES DES PATIENTS CANCEREUX METASTASIQUES
Classification
- CPC, 3
- G01N33/574
- G01N33/54326
- G01N2800/52
- IPC, 9
- C12M1 34
- C12N
- C12N1 00
- C12Q1 02
- G01N33 543
- G01N33 567
- G01N33 574
- G01N33 48
- G01N33 53
Designated states1
- Contracting states, 1
- Türkiye